Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-20

Study Completion Date

2018-12-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Assessment of short-term outcomes of ipsilateral lobe arterial devascularization of the large hepatocellular carcinoma: single center non-randomized trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC

NCT03313648

Hepatocellular Carcinoma Recurrent

UNKNOWN NA

Radiofrequency Versus Laser Ablation for Hepatocellular Carcinoma

NCT01096914

Carcinoma, Hepatocellular Neoplasms, Liver

COMPLETED NA

The Short-term Efficacy of Novel NTDP-RFA in the Treatment of Small HCC With Cirrhosis.

NCT04513119

Hepatocellular Carcinoma Stage I Radiofrequency Ablation

UNKNOWN

A Comparison Between Child-Pugh and Albumin-Bilirubin Scores

NCT03534843

Rupture, Spontaneous Rupture Liver Hepatocellular Carcinoma +1 more

COMPLETED

Study of Hemodynamic Conditions Measured During Hepatectomy

NCT03371537

Liver Dysfunction Circulatory; Change

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Assessment of the 30-day mortality and major complications as well as the tumor size changes of the patients undergoing ipsilateral lobe arterial devascularization of the large hepatocellular carcinoma. This is a prospective non randomized trial carried out at the Ribat University Hospital between April 2017 to March 2018.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Prospective and non-randomized clinical trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Devascularization

Patients undergoing ipsilateral hepatic artery ligation with extrahepatic collaterals division (HALED)

Group Type EXPERIMENTAL

HALED

Intervention Type PROCEDURE

This is attained via a laparotomy involves isolation of the arterial blood supply of the tumor-containing liver lobe (the ipsilateral hepatic artery as well as the extrahepatic arterial collaterals) while preserving the feeding veins.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HALED

This is attained via a laparotomy involves isolation of the arterial blood supply of the tumor-containing liver lobe (the ipsilateral hepatic artery as well as the extrahepatic arterial collaterals) while preserving the feeding veins.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Review and sign informed consent;
* Between 15 and 80 years of age at time of trial enrollment;
* Documented pathological and/or radiological diagnosis of hepatocellular carcinoma;
* Radiologically documented tumor size of \> 5 centimeters;
* Radiologically documented liver cirrhosis.

Exclusion Criteria

* American Anesthesia Association (ASA) Class IV or V and/or any contraindications to general anesthesia;
* Uncontrollable ascites;
* Deep persistent jaundice;
* Hepatic encephalopathy;
* Coagulopathy;
* Severe thrombocytopenia;
* Unable or unwilling to attend follow up visits and examinations;
* Other associated surgical procedure;

Minimum Eligible Age

15 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No